Heron Therapeutics (HRTX) Receives Daily News Impact Score of 0.14

News headlines about Heron Therapeutics (NASDAQ:HRTX) have been trending somewhat positive this week, Accern Sentiment reports. The research group identifies negative and positive media coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Heron Therapeutics earned a news impact score of 0.14 on Accern’s scale. Accern also gave news stories about the biotechnology company an impact score of 46.1304526201273 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.

Here are some of the news stories that may have effected Accern’s rankings:

Shares of Heron Therapeutics (NASDAQ HRTX) traded up $0.20 during trading on Friday, hitting $20.50. The stock had a trading volume of 843,393 shares, compared to its average volume of 1,010,000. The stock has a market capitalization of $1,130.00, a P/E ratio of -5.41 and a beta of 1.87. Heron Therapeutics has a 12-month low of $12.70 and a 12-month high of $24.80. The company has a current ratio of 2.12, a quick ratio of 2.02 and a debt-to-equity ratio of 0.62.

A number of brokerages have issued reports on HRTX. Oppenheimer reaffirmed a “buy” rating and issued a $27.00 target price on shares of Heron Therapeutics in a report on Friday, November 10th. BidaskClub lowered Heron Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, January 31st. Noble Financial reiterated a “buy” rating on shares of Heron Therapeutics in a research report on Sunday, November 12th. Cantor Fitzgerald reiterated a “buy” rating and issued a $31.00 price target on shares of Heron Therapeutics in a research report on Thursday, November 2nd. Finally, ValuEngine upgraded Heron Therapeutics from a “sell” rating to a “hold” rating in a research report on Friday, February 2nd. Three research analysts have rated the stock with a hold rating and ten have given a buy rating to the company. The company presently has an average rating of “Buy” and an average price target of $28.82.

In other news, VP Kimberly Manhard sold 7,584 shares of the stock in a transaction that occurred on Wednesday, January 10th. The stock was sold at an average price of $20.00, for a total value of $151,680.00. Following the completion of the sale, the vice president now directly owns 7,584 shares of the company’s stock, valued at $151,680. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Corporate insiders own 19.93% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This article was originally published by Sports Perspectives and is the property of of Sports Perspectives. If you are viewing this article on another publication, it was illegally stolen and republished in violation of U.S. and international trademark and copyright legislation. The original version of this article can be accessed at https://sportsperspectives.com/2018/02/10/heron-therapeutics-hrtx-receives-daily-news-impact-score-of-0-14.html.

About Heron Therapeutics

Heron Therapeutics, Inc is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology.

Insider Buying and Selling by Quarter for Heron Therapeutics (NASDAQ:HRTX)

Receive News & Ratings for Heron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply